HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedEUCTR 2013-000389-12

ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled Trial

This historical record does not confirm current site availability.

Historical research recordUnited KingdomSchizophrenia
The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations
United Kingdom
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
Not clearly listed
Sponsor
Cardiff University
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United Kingdom
Age range
Not clearly listed
Official registry ID
EUCTR 2013-000389-12
Official title
Show the full official title

ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

United Kingdom

Registry details
Historical country statuses
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Cardiff University, a university.

Want to explore more studies?

Explore studies